Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine

Lund‐Johansen, Per; Stranden, Einar; Helberg, Steiner; T, Wessel-Aas; Risberg, Knut; Rønnevik, Per K.; Istad, Helge; Madsbu, Sverre

doi:10.1097/00004872-200305000-00026

Cited by 60 publications

(44 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lercanidipine was well tolerated both when administered alone 15,16 and when given in combination with enalapril. The improved efficacy of combination therapy was therefore not associated with a worse tolerability of the treatment.…”

Section: Discussionmentioning

confidence: 98%

Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPM

Puig

Calvo

Luurila³

et al. 2007

J Hum Hypertens

View full text Add to dashboard Cite

This double-blind, placebo-controlled, four-way balanced design crossover study included hypertensive patients aged 60-85 years with mean office-measured sitting systolic blood pressure (SBP) 160-179 mm Hg and daytime SBP X135 mm Hg. After a 2-week run-in period, during which previous medications were discontinued, each patient received the following four treatments in randomized order for 4 weeks each: lercanidipine 10 mg (L), enalapril 20 mg (E), lercanidipine 10 mg plus enalapril 20 mg (L/E) and placebo (P). At the end of each treatment period, office trough blood pressure (BP) was measured and a 24-h Ambulatory Blood Pressure Monitoring (ABPM) was performed. Seventy-five patients (mean age 66 years, office BP 168/92 mm Hg, daytime SBP 151 mm Hg) were randomized and 62 completed the study with four valid postbaseline ABPMs. The administration of P, L, E and L/E was associated with a mean 24-h SBP of 144, 137, 133 and 127 mm Hg, respectively. All active treatments significantly reduced the mean 24-h SBP in comparison with placebo, but L/E was significantly more effective than L and E alone. Similarly, office SBP was significantly more reduced with L/E (À16.9 mm Hg) than with L (À5.0 mm Hg) or E (À5.9 mm Hg). A BP o140/90 mm Hg was recorded in 18% of patients with L, 19% with E and 45% with L/E. Two patients on P and two on L/E were withdrawn from the study due to adverse events. In conclusion, combination therapy with L/E has additive antihypertensive effects on both ambulatory and office BP in elderly patients and is well tolerated.

show abstract

Section: Discussionmentioning

confidence: 98%

Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPM

Puig

Calvo

Luurila³

et al. 2007

J Hum Hypertens

View full text Add to dashboard Cite

show abstract

“…However, when reported by patients as 'leg swelling', one of these thirdgeneration CCBs has been associated with an oedema incidence of 22%. 26 Thus, although differences among CCBs in oedema incidence rates have been reported in a number of studies, 10,[27][28][29][30] it is evident that dose-dependent peripheral oedema remains a common side effect in patients receiving both established and newer CCBs. 10,31 Factors that may influence oedema Several factors can predispose the patient to an increased risk of oedema.…”

Section: Mechanism Of Ccb-induced Oedemamentioning

confidence: 99%

“…28 In a second example, physical examination of CCB-treated patients by the investigator led to a reported oedema incidence of 10%. 26 However, when patient reports of 'leg swelling' were used as the assessment criterion for oedema in the same study, the incidence was 22%. There is also evidence that patients do not report all symptoms that they suspect to be related to drug administration to their doctor, and that physicians do not always record symptoms reported to them by patients.…”

mentioning

confidence: 94%

Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin–angiotensin system

Sierra

2009

J Hum Hypertens

View full text Add to dashboard Cite

This review is aimed at examining calcium channel blocker (CCB)-related oedema and how this can be attenuated through the use of agents that inhibit the renin-angiotensin system. CCBs are effective antihypertensive agents, but their propensity for causing oedema may reduce compliance. A review of the literature has indicated that the absolute incidence of this side effect is difficult to determine because reported rates vary widely, a factor that may stem from differences in the surveillance technique (active vs passive). In a recent trial incorporating active surveillance, 25% of patients who received amlodipine 10 mg per day experienced oedema. CCB-induced oedema is caused by increased capillary hydrostatic pressure that results from preferential dilation of pre-capillary vessels. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) cause postcapillary dilation and normalize hydrostatic pressure, and are thus ideally suited for prevention/reversal of CCB-induced oedema. The efficacy of this strategy was proven using both subjective and objective techniques. ARB/CCB and ACEI/CCB combination therapy is also more effective than CCB monotherapy in controlling blood pressure. These combinations represent an important advance in the management of hypertension.

show abstract

“…In clinical studies, peripheral edema, as a pharmacologically-mediated adverse event, has typically been captured through water-displacement volumetry, patient self-report, or other, often non-validated, investigator assessments. [20][21][22][23][24][25] Water-displacement volumetry is widely considered to be the reference method of edema assessment; 26 however, it is also considered to be time-consuming, difficult to perform, and inappropriate in some clinical situations (e.g., postoperative), limiting the use of this method. 12,27 Documentation of the accuracy and reliability of other methods of measuring peripheral edema vary.…”

Section: Assessment Of Peripheral Edemamentioning

confidence: 99%

Reliability and Feasibility of Methods to Quantitatively Assess Peripheral Edema

Brodovicz¹,

McNaughton²,

Uemura³

et al. 2009

Clinical Medicine & Research

128

View full text Add to dashboard Cite

Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine

Abstract: In postmenopausal females with mild to moderate hypertension the oedema formation of Lercanidipine was significantly less than that of Amlodipine, despite no significant differences in the antihypertensive effect.

Cited by 60 publications

References 20 publications

Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPM

Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPM

Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin–angiotensin system

Reliability and Feasibility of Methods to Quantitatively Assess Peripheral Edema

Contact Info

Product

Resources

About